Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena Pharmaceuticals has announced that initial clinical study results for oral APD668 suggest that glucose-dependent insulinotropic receptors, or GDIRs, may improve glucose control in patients with type 2 diabetes.
Subscribe to our email newsletter
APD668 is an oral drug candidate discovered by Arena and being investigated under a partnership with Ortho-McNeil Pharmaceutical.
Ortho-McNeil’s initial clinical studies evaluated healthy volunteers and patients with type 2 diabetes in randomized, double-blind, placebo-controlled trials evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple (14 day) escalating doses of APD668. Based on the data from those studies, Ortho-McNeil has decided to put APD668 on hold and has advanced a potentially more potent Arena discovered GDIR agonist into preclinical development.
Dominic Behan, Arena’s senior vice president and chief scientific officer, said: “We are encouraged by the clinical study results supporting GDIR agonists as effective modulators of glucose homeostasis in patients with type 2 diabetes, and we look forward to the results of Ortho-McNeil advancing another of Arena’s GDIR compounds into development.”